Literature DB >> 30837195

A randomized study of botulinum toxin versus botulinum toxin plus physical therapy for treatment of cervical dystonia.

Wei Hu1, Valerie Rundle-Gonzalez1, Shankar J Kulkarni2, Daniel Martinez-Ramirez1, Leonardo Almeida1, Michael S Okun1, Aparna Wagle Shukla3.   

Abstract

BACKGROUND: Physical therapy (PT) for cervical dystonia is not well studied, and the underlying physiological effects are not known.
METHODS: We enrolled 26 subjects comprising of 16 cervical dystonia and 10 healthy controls for normative physiological data. We randomized cervical dystonia patients who reported suboptimal benefits on botulinum toxin (BoNT) injections to BoNT alone (BoNT arm) or BoNT plus PT (PT-BoNT arm). PT-BoNT arm received manual PT on the injection day followed by six weeks of home-exercise program. Home-exercise program comprised of stretching, range-of-motion and isometric exercises. The primary outcome was change from baseline in Toronto Western spasmodic torticollis rating scale (TWSTRS) that was recorded six weeks after exercise program. TWSTRS was video evaluated by blinded raters. We probed sensorimotor plasticity with transcranial magnetic stimulation (TMS) using a paired associative stimulation (PAS) paradigm.
RESULTS: TWSTRS score improved (severity 31%, p = 0.002; pain 28%, p = 0.01) and PAS plasticity decreased (p = 0.01) in PT-BoNT arm compared to BoNT arm. PAS values for PT-BoNT arm were found to approach values of healthy control values. Change in PAS measure correlated significantly with TWSTRS change (severity, r = 0.56, p = 0.04; pain, r = 0.61, p = 0.03. TWSTRS disability score only approached significance (p = 0.14) when comparing the two treatment arms.
CONCLUSION: PT is a potential adjunct in patients with cervical dystonia who report suboptimal benefits with BoNT therapy. PT related benefits in cervical dystonia are likely mediated through modulation of sensorimotor plasticity.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Botulinum toxin; Cervical dystonia; Dystonia; Physical therapy

Mesh:

Substances:

Year:  2019        PMID: 30837195     DOI: 10.1016/j.parkreldis.2019.02.035

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  7 in total

1.  Needs and Perceptions of Patients With Dystonia During the COVID-19 Pandemic: A Qualitative Framework Analysis of Survey Responses From Italy.

Authors:  Vittorio Rispoli; Matías Eduardo Díaz Crescitelli; Francesco Cavallieri; Francesca Antonelli; Stefano Meletti; Luca Ghirotto; Franco Valzania
Journal:  Front Neurol       Date:  2022-06-16       Impact factor: 4.086

Review 2.  Treatment of Dystonia: Medications, Neurotoxins, Neuromodulation, and Rehabilitation.

Authors:  Ian O Bledsoe; Aaron C Viser; Marta San Luciano
Journal:  Neurotherapeutics       Date:  2020-10-23       Impact factor: 7.620

Review 3.  Botulinum Toxin in Movement Disorders: An Update.

Authors:  Charenya Anandan; Joseph Jankovic
Journal:  Toxins (Basel)       Date:  2021-01-08       Impact factor: 4.546

Review 4.  The Central Effects of Botulinum Toxin in Dystonia and Spasticity.

Authors:  Pavel Hok; Tomáš Veverka; Petr Hluštík; Martin Nevrlý; Petr Kaňovský
Journal:  Toxins (Basel)       Date:  2021-02-17       Impact factor: 4.546

5.  KinesioTaping after botulinum toxin type A for cervical dystonia in adult patients.

Authors:  Małgorzata Dec-Ćwiek; Karolina Porębska; Katarzyna Sawczyńska; Marcin Kubala; Magdalena Witkowska; Kinga Zmijewska; Jakub Antczak; Joanna Pera
Journal:  Brain Behav       Date:  2022-03-03       Impact factor: 3.405

6.  Adjuvant medical therapy in cervical dystonia after deep brain stimulation: A retrospective analysis.

Authors:  Alfonso E Martinez-Nunez; Christos Sidiropoulos; Julia Wall; Jason Schwalb; Ellen Air; Peter LeWitt; Bisena Bulica; Patricia Kaminski; Neepa Patel
Journal:  Front Neurol       Date:  2022-08-05       Impact factor: 4.086

Review 7.  Neurorehabilitation in dystonia: a holistic perspective.

Authors:  Lynley V Bradnam; Rebecca M Meiring; Melani Boyce; Alana McCambridge
Journal:  J Neural Transm (Vienna)       Date:  2020-10-24       Impact factor: 3.575

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.